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ABSTRACT
Objective To determine the comparative effects of the
thiazolidinediones (rosiglitazone and pioglitazone) on
myocardial infarction, congestive heart failure, and
mortality in patients with type 2 diabetes.
Design Systematic review and meta-analysis of
observational studies.
Data sources Searches of Medline and Embase in
September 2010.
Study selection Observational studies that directly
compared the risk of cardiovascular outcomes for
rosiglitazone and pioglitazone among patients with type
2 diabetes mellitus were included.
Data extraction Random effects meta-analysis (inverse
variance method) was used to calculate the odds ratios
for cardiovascular outcomes with thiazolidinedione use.
The I2 statistic was used to assess statistical
heterogeneity.
Results Cardiovascular outcomes from 16 observational
studies (4 case-control studies and 12 retrospective
cohort studies), including 810000 thiazolidinedione
users, were evaluated after a detailed review of 189
citations. Compared with pioglitazone, use of
rosiglitazone was associated with a statistically
significant increase in the odds of myocardial infarction
(n=15 studies; odds ratio 1.16, 95% confidence interval
1.07 to 1.24; P<0.001; I2=46%), congestive heart failure
(n=8; 1.22, 1.14 to 1.31; P<0.001; I2=37%), and death
(n=8; 1.14, 1.09 to 1.20; P<0.001; I2=0%). Numbers
needed to treat to harm (NNH), depending on the
population at risk, suggest 170 excess myocardial
infarctions, 649 excess cases of heart failure, and 431
excess deaths for every 100 000 patients who receive
rosiglitazone rather than pioglitazone.
Conclusion Among patients with type 2 diabetes, use of
rosiglitazone is associated with significantly higher odds
of congestive heart failure, myocardial infarction, and
death relative to pioglitazone in real world settings.
INTRODUCTION
Troglitazone, the first thiazolidinedione, was withdrawn
from themarket because of liver toxicity.1Muraglitazar,
a dual peroxisome proliferator activated receptor
(PPAR) agonist, failed to achieve regulatory approval
because of concerns about adverse cardiovascular
events.2 Rosiglitazone and pioglitazone are the available
thiazolidinediones inNorth America, but meta-analyses
of randomised controlled trials have suggested an
increased risk of ischaemic cardiovascular events with
rosiglitazone.34 In contrast,meta-analysis of trials of pio-
glitazone indicates the possibility of an ischaemic cardio-
vascular benefit.5 Robust evidence also shows that both
drugs increase the risk of congestive heart failure and
fractures, but whether any meaningful difference exists
in the magnitude of risk between the two thiazolidine-
diones is not known.67 The European Medicines
Agency has recommended the suspension of marketing
authorisation for rosiglitazone, whereas the US Food
and Drug Administration has allowed the continued
marketing of rosiglitazone with additional restrictions.8
No long term trials with cardiovascular outcomes
have directly compared these two drugs. Clinical trials
have strict selection criteria that may exclude partici-
pants at high risk of adverse events, and adverse
cardiovascular outcomes can be rare in such trials.9
On the other hand, population based observational
studies resemble clinical practice, where patients may
have risk factors for cardiovascular disease or comor-
bidities. Therefore, consideration of the evidence from
carefully conducted observational studies is essential
to determine if any difference in cardiovascular events
or mortality exists between the two drugs.
Our objective was to systematically determine the
comparative effects of rosiglitazone and pioglitazone
on cardiovascular outcomes (myocardial infarction
and congestive heart failure) andmortality from obser-
vational studies in patients with type 2 diabetes. We
aimed specifically to calculate the pooled odds ratios
for adverse cardiovascular events with rosiglitazone
compared with pioglitazone—that is, the relative like-
lihood of cardiovascular harm if rosiglitazonewas used
rather than pioglitazone.
METHODS
Eligibility criteria
We selected controlled observational (non-randomised)
studies that reported on cardiac outcomes in patients
receiving rosiglitazone compared with pioglitazone.
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We included studies of a cohort or case-control design
that enrolled participants with type 2 diabetes mellitus.
The primary outcome of interest was myocardial infarc-
tion. Secondary outcome measures were congestive
heart failure and overall mortality. Eligible studies had
to present one of the following: odds ratio, relative risk,
hazard ratio, or sufficient raw data to enable calculation
of the odds ratio where not otherwise reported.
Search strategy
We searched Medline and Embase by using Ovid SP
(from inception to the end of September 2010), with
the search terms (pioglitazone or rosiglitazone or thia-
zolidinedione$).mp and (myocardial-infarction or
cardiovascular or cardiac or heart).mp and (cohort or
case-control or observational or retrospective).mp.We
did not use any language restrictions, but we limited
the search to human studies. Additionally, we signed
up with PubMed to receive automated electronic noti-
fication of any newarticles containing the above search
terms. To identify unpublished studies, we reviewed
the regulatory authorities websites (US Food and
Drug Administration and European Medicines
Agency), as well as the study registers of the drugman-
ufacturers GlaxoSmithKline and Takeda.We checked
the bibliographies of included studies and recent
review articles for additional relevant articles.
Study selection and data extraction
Two reviewers (CSK and YKL or SS) checked all titles
and abstracts for studies that could potentiallymeet the
inclusion criteria. We retrieved full reports of these
potentially eligible studies for detailed assessment by
two reviewers (CSK and YKL), who then indepen-
dently extracted information on study design, drug
use, study location, characteristics of participants, and
relevant outcomes on to a preformatted spreadsheet.
Any uncertainties or discrepancies between the two
reviewers were resolved through consensus after re-
checking of the source data and consultation with the
third reviewer. We also contacted authors if any areas
of uncertainty needed clarification.
Where different timings and durations of thiazolidi-
nedione usewere reported in the studyparticipants, we
pre-specified that data would be preferentially extra-
cted from the participants with current or most recent
use, until cessation of treatment. We also aimed to
extract risk estimates pertaining to overall use in the
entire cohort rather than in any specific subgroups.
Risk of bias
In accordance with the recommendations of the
Cochrane Adverse Effects Methods Group, we
checked the methods of selection of participants
(including baseline characteristics and adjustment for
confounders), nature of follow-up, ascertainment of
drug use, and definition and monitoring of adverse
outcomes.10 To counter selective reporting bias, we
contacted authors when relevant cardiovascular out-
comes were potentially measured but were not
reported or were stated to be non-significant. We
used a funnel plot to assess publication bias.
Data analysis
We used RevMan 5.0.25 (Nordic Cochrane Centre) to
do random effects meta-analysis using the inverse var-
iancemethod for pooled odds ratios.Weused the fixed
effectsmodel for sensitivity analysis.Weassumed simi-
larity between the odds ratio and other relative mea-
sures such as relative risk, rate ratios, or hazard ratios
because cardiovascular events and deaths were rare
events.11
Where possible, we aimed to pool adjusted odds
ratios from the primary studies; otherwise, we used
raw outcome data to yield unadjusted odds ratios. In
view of the potential diversity of study designs, we
grouped the studies for the analysis according to stu-
dies for which only the unadjusted odds ratios were
available, with no correction for baseline differences
or confounding, and those for which we were able to
extract odds ratios adjusted for potential confounders.
For consistency in direction of risk comparisons, we
used the odds ratio to assess the magnitude of risk for
rosiglitazone use compared with that for pioglitazone
use. For studies that reported the odds ratio for piogli-
tazone compared with rosiglitazone, we used the reci-
procal of the point estimate and the bounds of the
confidence intervals.
We estimated the number needed to treat to harm
per year (NNH) (and 95% confidence interval) by
applying the pooled odds ratio from the meta-analysis
to the annual rate of the event in different
populations.12 The NNH is the number of patients
with type 2 diabetes who need to be treated with rosi-
glitazone rather than pioglitazone for one additional
patient to have an adverse outcome.
Potentially relevant studies for full checking (n=36)
Titles and abstracts screened for studies
that might be potentially relevant (n=189)
Observational studies with direct comparison of cardiac
outcomes or mortality for rosiglitazone v pioglitazone (n=16)
Articles retrieved by
checking titles in GSK
study register (n=4)
Articles retrieved from
PubMed and Embase
search (n=185)
Review articles, trial reports, or clearly not observational
studies of cardiovascular events with rosiglitazone v
pioglitazone in patients with type 2 diabetes (n=153)
Excluded (n=20):
  Did not report on direct comparison of rosiglitazone
    v pioglitazone (n=15)
  Earlier study that used same database population as
    a later study (n=1)
  Had duplicate data (n=4)
Fig 1 | Flow diagram of process of selection of articles for
meta-analysis. GSK=GlaxoSmithKline
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Table 1 | Design and characteristics of included studies
Studies Study design and data source No of patients
Mean
age
%
male Selection criteria Risk estimates (95% CI)
Bilik 201014 Retrospectivecohort study(TRIAD);
community patients; USA, 1999 to
2003
564 rosiglitazone;
334 pioglitazone
(in health plans in which
both thiazolidinediones
were available)
59 48 Type 2 diabetes, age >18 years, not pregnant,
community dwelling, English or Spanish speaking, and
enrolled in health plan for ≥18 months; excluded
if >1 type of thiazolidinedione prescription
Where both
thiazolidinediones were
available on formulary:
MI HR 1.3 (0.31 to 5.37);
mortality 0.69 (0.28 to 1.69)
Brownstein
201015
Retrospective cohort study in
Partners Healthcare System
covering hospital and community
patients; USA, January 2000 to July
2006
1879 rosiglitazone;
806 pioglitazone
64 52 Aged >18 years with diabetes or HbA1C >6% and
≥1 oral diabetes drug; excluded if used metformin
or thiazolidinedione for polycystic ovaries
Based on entire cohort with
adjustment for known risk
factors: MI RR 1.7 (1.1 to 2.6)
Dormuth
200916
Nested case-control study;
hospital and community patients;
Pharmanet database, BC, Canada,
May 2003 to March 2007
Acute MI: 2244 cases and
8903 controls; drug use:
462 rosiglitazone and
235 pioglitazone
66 74 Previous metformin users; excluded if received other
oral antidiabetic drug or insulin within 365 days before
startingmetformin or emigrated/died beforeMay 2003
Based on overall use:
MI OR 1.00 (0.67 to 1.49)
Graham 201017 New user inception cohort;
community patients; Medicare,
USA, July 2006 to June 2009
67 593 rosiglitazone;
159 978 pioglitazone
74 60 ≥6 month enrolment and >65 years who started
rosiglitazone or pioglitazone; excluded if residing
in a hospital, long term care home, or hospice
MI HR 1.06 (0.96 to 1.18);
HF 1.25 (1.16 to 1.34);
mortality 1.14 (1.05 to 1.24)
Hsiao 200918 Retrospective cohort study; NHI
claims database, Taiwan, 2000 to
2005
49 624 rosiglitazone;
12 010 pioglitazone
61 53 Newly diagnosed type 2 diabetes with ≥3 prescriptions
oforal diabetesdrug;excluded if had type1diabetesor
had been on insulin during study period
Unadjusted data for entire
cohort: MI ros 1984/49 624,
pio 356/12 010; HF ros 664/
49 624, pio 115/12 010
Juurlink 200919 Retrospective new user cohort
study; Ontario Public Drug Benefit
Program, Canada, 2002 to 2008
16 951 rosiglitazone;
22 785 pioglitazone.
Median
72
53 Residents of Ontario, >66 years of age starting
thiazolidinedione treatment; excluded if using insulin
MI HR 1.05 (0.90 to 1.23); HF
1.30 (1.15 to 1.45); mortality
1.16 (1.02 to 1.33)
Koro 200820 Nested case-control study within
diabetes cohort of Integrated
HealthCare Information Services
claims database; USA, 1999 to
2006
MI: 9870 cases and
29610 controls; drug use:
3839 rosiglitazone and
3343 pioglitazone
63 68 Patientswith type 2 diabetes and ≥1 prescription claim
for antidiabetic drug, with ≥1 year enrolment in
healthcare plan; those with heart failure or ischaemic
heart disease were included, but those with MI were
excluded
MI OR 1.12 (0.99 to 1.26)
Lipscombe
200721
Nested case-control study;
community patients; Ontario,
Canada, 2002 to 2005
1886current rosiglitazone
users; 929 current
pioglitazone users
61 74 Aged ≥66 years with diabetes and dispensed ≥1 oral
hypoglycaemic agent in study period; excluded if
received insulin in year preceding cohort entry
Unadjusted data current
users: MI ros 335/1886, pio
134/920; HF ros 426/1907,
pio 160/929; mortality ros
434/1716 pio 165/715
Margolis
200822
Retrospective cohort study;
community patients in THIN GP
database; UK, 2002 to 2006
7282 rosiglitazone;
2244 pioglitazone
NA 54 Patients with two records of diabetes between 2002
and 2006 and ≥40 years old
Full cohort: MI or CAD HR 1.0
(0.8 to 1.3)
Pantalone
200923
Retrospective cohort study;
Cleveland Clinic Electronic Health
Records; USA, October 1998 to
October 2006
1079 rosiglitazone;
1508 pioglitazone
61 47 Type 2 diabetes with prescription for rosiglitazone,
pioglitazone, metformin, or sulfonylurea, age >18 years
with no history of dialysis, CAD, or HF; excluded if
prescribed insulin or multiple oral agents
HF HR 0.84 (0.52 to 1.35);
mortality 1.23 (0.79 to 1.92)
Stockl 200924 Nested case-control study; claims
database of Prescription Solutions
cohort in 5 states in USA, January
2000 to June 2006
MI: 1681 cases and
6653 controls; drug use:
1039 rosiglitazone and
294 pioglitazone
70 55 Patients aged 18-84 years with a filled prescription for
antidiabetic drug or exenatide during study period;
excluded if had type 1 diabetes, cancer, renal or liver
failure, organ transplantation, or HIV infection
MI OR 1.26 (0.79 to 2.00)
Tzoulaki
200925
Retrospective cohort study;
community patients; UK General
Practice Research Database,
January 1990 to December 2005
140 082 rosiglitazone;
45 807 pioglitazone
65 52 Patients aged 35-90 years with episode of care
between 1990 and 2005 associated with clinical or
referred event for diabetes; excluded if date of death
unclear
MI HR 1.34 (0.86 to 2.09);
HF 1.04 (0.75 to 1.44);
mortality 1.36 (1.05 to 1.76)
Walker 200826 Retrospective cohort study;
pharmacy and medical claims
database (Pharmetrics) covering
>80 health plans; USA, 2000 to
2007
57 000 rosiglitazone;
51 000 pioglitazone
<65 NA Users of oral hypoglycaemic agents who had
≥6 months’ membership in health plan, age >18 years;
excluded if in health plans for which data had been
previously used in similar studies
On treatment summary:
MI 1.21 (0.95 to 1.54)
Wertz 201027 Retrospective cohort study;
medical/pharmacy claims in
WellPoint database; USA, January
2001 to December 2005
18 319 rosiglitazone;
18 309 pioglitazone
54 58 Aged >18 years with new rosiglitazone or pioglitazone
claim; excluded if not in health plan >365 days before
index date or had pre-index pharmacy claim of insulin;
those with previous cardiovascular events were not
excluded
MI HR 0.94 (0.75 to 1.18); HF
1.10 (0.94 to 1.31); mortality
1.02 (0.86 to 1.21)
Winkelmayer
200828
New user cohort study; Medicare
database in New Jersey and
Pennsylvania, USA, January 2000
to December 2005
14 101 rosiglitazone;
14 260 pioglitazone
76 26 Age >65 years with new prescription for
thiazolidinedione; excluded if used troglitazone or
fixed dose combination with metformin
On-drug analysis:MI IRR 1.08
(0.93 to 1.25); HF 1.13 (1.01
to 1.26); mortality 1.15 (1.05
to 1.26)
Ziyadeh 200929 Retrospective cohort study; i3
proprietary research database of
medical claims inUSA, July2000 to
March 2007
47 501 rosiglitazone;
47 501 pioglitazone
NA 57 Age >18 years, starting rosiglitazone or pioglitazone,
followed by >6 months of health plan membership;
troglitazone users excluded
Based on censoring at
discontinuation of treatment
(regimen stop): MI HR 1.41
(1.13 to 1.75)
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Statistical heterogeneity
We used the I2 statistic to assess statistical heterogene-
ity. I2 values of 30-60% represented amoderate level of
heterogeneity.13
RESULTS
Figure 1 shows the process of selection of studies. We
retrieved 16 observational studies involving 810 000
thiazolidinedione users (429 000 patients taking rosi-
glitazone and 381 000 taking pioglitazone), after a
detailed review of 189 citations.14-29 Fifteen studies
reported on the outcome of myocardial infarction,
eight studies reported on the outcome of congestive
heart failure, and eight studies reported on mortality.
We found 12 retrospective cohort studies and four
case-control studies. The mean or median follow-up
time ranged from 105 days to 7.1 years. Four studies
reported duration of thiazolidinedione use, with a
range of 215 to 450 days. Themean age of participants
ranged from 54 to 76 years across studies, but most
study participants were generally aged above
60 years; only two studies reported the average age of
their participants as under 60 years. An average of 55%
of patients were male across 15 studies. Table 1 shows
themain characteristics of the studies and participants;
table 2 shows the outcomes, interventions, and quality
assessments.
Risk of bias
The included studies were broadly similar in terms of
ascertainment of drug use and cardiovascular out-
comes (table 2); they relied mainly on computerised
diagnostic codes, pharmacy claims databases, and ret-
rospective chart reviews. Few researchers made
attempts to verify drug history directly with the
patients or to check the validity of the prescriptions
data source; only one study was deemed to have spe-
cific validation of drug use. 14Most studies reported the
accuracy of outcome ascertainment on the basis of his-
torical validation studies; only two studies specifically
cross checked or validated outcomes for this
analysis. 15 23 Both of these studies showed a limited
degree of misclassification.15 23
None of the studies provided details about the sever-
ity and consequences of the cardiac adverse events.
Almost all the studies used a wide variety of variables
to adjust for potential confounders. Two cohort studies
checked specifically for similarities between the rosigli-
tazone and pioglitazone populations and did not find
any major differences in the characteristics
evaluated.17 19 We were able to use adjusted risk esti-
mates for most studies, except for two studies for
which we calculated odds ratios from the raw
data.18 21
Myocardial infarction
Compared with pioglitazone, use of rosiglitazone was
associated with a significantly increased odds of myo-
cardial infarction from 15 studies (pooled odds ratio
1.16, 95% confidence interval 1.07 to 1.24; P<0.001)
(fig 2). We found a moderate level of heterogeneity
(I2=46%) for the pooled results for myocardial infarc-
tion, which stemmed from combining the unadjusted
and adjusted studies together for the overall estimate.
Heart failure
Based on the pooled results of eight studies, the odds of
congestive heart failure were statistically significantly
higher for rosiglitazone than for pioglitazone (odds
ratio 1.22, 1.14 to 1.31; P<0.001), withmoderate statis-
tical heterogeneity (I2=37%) (fig 3).
Overall mortality
The odds of deathwere statistically significantly higher
for rosiglitazone than for pioglitazone when we pooled
eight studies, with an odds ratio of 1.14 (1.09 to 1.20;
P<0.001) (fig 4). We found no evidence of statistical
heterogeneity for this outcome (I2=0%).
Number needed to treat for harm
In a low risk population (age 45-64 years) with type 2
diabetes but no previous history of myocardial infarc-
tion, the underlying incidence ofmyocardial infarction
Adjusted odds ratio
  Bilik 201014
  Brownstein 201015
  Dormuth 200916
  Graham 201017
  Juurlink 200919
  Koro 200820
  Margolis 200822
  Stockl 200924
  Tzoulaki 200925
  Walker 200826
  Wertz 201027
  Winkelmayer 200828
  Ziyadeh 200929
Subtotal (95% CI)
Test for heterogeneity: τ2=0.00,
  χ2=14.25, df=12, P=0.28, I2=16%
Test for overall effect: z=3.19, P=0.001
Unadjusted odds ratio
  Hsiao 200918
  Lipscombe 200721
Subtotal (95% CI)
Test for heterogeneity: τ2=0.00,
  χ2=0.34, df=1, P=0.56, I2=0%
Test for overall effect: z=5.68, P<0.001
Total (95% CI)
Test for heterogeneity: τ2=0.01,
  χ2=25.89, df=14, P=0.03, I2=46%
Test for overall effect: z=3.87, P<0.001
1.30 (0.31 to 5.37)
1.70 (1.10 to 2.60)
1.00 (0.67 to 1.49)
1.06 (0.96 to 1.18) 
1.05 (0.90 to 1.23) 
1.12 (0.99 to 1.26)
1.00 (0.80 to 1.30)
1.26 (0.79 to 2.00)
1.34 (0.86 to 2.09)
1.21 (0.95 to 1.54)
0.94 (0.75 to 1.18)
1.08 (0.93 to 1.25)
1.41 (1.13 to 1.75)
1.11 (1.04 to 1.18)
1.36 (1.22 to 1.53) 
1.27 (1.02 to 1.58)
1.34 (1.21 to 1.48)
1.16 (1.07 to 1.24)
0.3
2.5
2.8
13.1
9.8
11.9
6.0
2.2
2.4
6.0
6.6
10.3
6.9
80.8
12.3
6.9
19.2
100.0
0.5 0.7 1.0 1.5 2.0
Study or subgroup
Pioglitazone
more harmful
Rosiglitazone
more harmful
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Weight
(%)
Fig 2 | Meta-analysis of odds ratio for myocardial infarction with rosiglitazone versus
pioglitazone
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was 1.08% per year.30 Use of rosiglitazone here would
result in an annual NNHof 587 (95% confidence inter-
val 392 to 1339). This can be equated to 170 excess
myocardial infarctions for every 100 000 patients
who received rosiglitazone rather than pioglitazone.
In a US cohort of patients with type 2 diabetes, the
baseline incidence of heart failure was found to be
3.08% per year.31 Use of rosiglitazone here would
result in an annual NNH of 154 (110 to 241). This
can be equated to 649 excess cases of heart failure for
every 100 000 patients who received rosiglitazone
rather than pioglitazone.
In a large French registry study of patients with type
2 diabetes and atherosclerosis, the underlying mortal-
ity rate was found to be 3.15% per year.32 Use of rosi-
glitazone here would result in an annual NNH of 232
(163 to 360). This can be equated to 431 excess deaths
for every 100 000 patients who received rosiglitazone
rather than pioglitazone.
Sensitivity analysis
Meta-analysis using the fixed effects model yielded
estimates that were similar in direction and magnitude
to those from the random effects model formyocardial
infarction (odds ratio 1.15, 1.10 to 1.21), heart failure
(1.23, 1.17 to 1.29), and overall mortality (1.14, 1.09 to
1.20).
In view of potential patient selection bias arising
after publication of a meta-analysis in May 2007 that
showed increasedmyocardial risk with rosiglitazone,33
we did a post hoc analysis by excluding the single study
that had a substantial proportion of patients recruited
after May 2007.17 This did not appreciably change the
direction and magnitude of the estimates for myo-
cardial infarction (odds ratio 1.17, 1.08 to 1.27), heart
failure (1.21, 1.10 to 1.33), and overall mortality (1.13,
1.04 to 1.24). Further exclusion of another study
(recruitment dates 2002 to 2008) did not appreciably
change the odds ratios for myocardial infarction (1.19,
1.09 to 1.29), heart failure (1.18, 1.06 to 1.33), andover-
all mortality (1.14, 1.06 to 1.22).19
Assessment of publication bias
The funnel plot showed that risk estimates stemmed
mostly from large, precise studies that seemed to be
fairly well distributed, with no definite evidence of
asymmetry (fig 5).
DISCUSSION
Our results suggest a modest but statistically significant
increase in the odds of myocardial infarction (approxi-
mately 16%), congestive heart failure (approximately
23%), and mortality (approximately 14%) with use of
rosiglitazone compared with those for pioglitazone use
in realworld studies amongpatientswith type2diabetes.
The consistency in the magnitude of increased risk for
the different cardiac outcomes, as well asmortality, indi-
cates that this is unlikely to be a chance finding. Other
strengths of our analysis include the large number of
thiazolidinedione users (around 810000) and the
absence of substantial statistical heterogeneity, which
suggests that the risk is maintained across most popula-
tions and is unaffected by geographical variations.
Comparison with other studies
Our synthesis of evidence from observational studies
extends the findings of a cardiovascular hazard with
rosiglitazone from meta-analysis of clinical trials to
real world settings and suggests the possibility of a
cardiovascular difference between the two drugs.3-5
Adjusted indirect comparisons of the risk estimates
from meta-analysis of myocardial infarction and heart
failure in randomised controlled trials shows that rosi-
glitazone is associated with an increased relative risk of
1.58 (95% confidence interval 1.14 to 2.20) for myo-
cardial infarction and 1.48 (1.01 to 2.18) for heart fail-
ure, compared with pioglitazone.3-5 34 The direction of
effect for both outcomes is consistent with our analysis,
whereas the relatively lower point estimates seen in our
analysis may reflect the generally more conservative
nature of estimates of harm that has been noted with
observational studies.35 Participants in trials may differ
from those in observational studies, because most of
the observational studies recruited a wider, more gen-
eralisable rangeof patients by not enforcing rigid inclu-
sion and exclusion criteria relating to comorbid
conditions. Of the 16 included studies, two excluded
patients with existing cardiac conditions (so that they
could study incident disease)20 23 and only one
excluded patients who had comorbidities such as
renal or liver disease.
Adjusted odds ratio
  Graham 201017
  Juurlink 200919
  Pantalone 200923
  Tzoulaki 200925
  Wertz 201027
  Winkelmayer 200828
Subtotal (95% CI)
Test for heterogeneity: τ2=0.00,
  χ2=7.88, df=5, P=0.16, I2=37%
Test for overall effect: z=4.58, P<0.001
Unadjusted odds ratio
  Hsiao 200918
  Lipscombe 200721
Subtotal (95% CI)
Test for heterogeneity: τ2=0.00,
  χ2=0.01, df=1, P=0.91, I2=0%
Test for overall effect: z=4.58, P<0.001
Total (95% CI)
Test for heterogeneity: τ2=0.00,
  χ2=11.20, df=7, P=0.13, I2=37%
Test for overall effect: z=5.64, P<0.001
1.25 (1.16 to 1.34)
1.30 (1.15 to 1.45)
0.84 (0.52 to 1.35)
1.04 ( 0.75 to 1.44)
1.10 (0.94 to 1.31)
1.13 ( 1.01 to 1.26)
1.19 (1.10 to 1.28)
1.40 (1.15 to 1.71)
1.38 (1.13 to 1.69)
1.39 (1.21 to 1.60)
1.22 (1.14 to 1.31)
26.9
18.5
2.0
4.1
12.1
18.1
81.6
9.3
9.1
18.4
100.0
0.5 0.7 1.0 1.5 2.0
Study or subgroup
Pioglitazone
more harmful
Rosiglitazone
more harmful
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Weight
(%)
Fig 3 | Meta-analysis of odds ratio for heart failure with rosiglitazone versus pioglitazone
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Table 2 | Drug use, study outcomes, and potential sources of bias
Studies Ascertainment of drug use Ascertainment of outcomes Adjustment for confounders
Bilik 201014 Ascertained by health plan records
for prescriptions filled; average of
19 months’ use
MI and all cause mortality ascertained by ICD codes on
health plan administrative data and national death
index
Age, sex, race, income, history of diabetic nephropathy, history of
cardiovascular disease, insulin use, and health plan
Brownstein
201015
Based on electronic records and
randomly checked case notes/
discharge summaries, with 94%
sensitivity and specificity for drug
use
MI ascertainment based on ICD codes and randomly
selected case notes/discharge summaries with
sensitivity of 94% and specificity of 74% for outcomes
Age, sex, cardiovascular disease, antihypertensive and lipid lowering
drugs, and Charlson score
Dormuth 200916 Pharmanet database of
prescriptions dispensed at
community pharmacies (data
quality checks done by Pharmanet)
MI ascertainment based on ICD codes of hospital
admission records (primary reason for admission)
collected by Ministry of Health; controls were patients
starting metformin matched on age, sex, number of
family members, health plan enrolment, and income
Duration of diabetes; congestive heart failure; angiography;
revascularisation; ischaemic stroke; TIA; previous MI; angina; renal
disease; Romano comorbidity score; use of cardiac drugs, clopidogrel, and
insulin; and past use of metformin, glitazones, and sulfonylureas
Graham 201017 Drug claims linked to Medicare
database for prescription drugs
from January 2006; median follow-
up 105 days
MI and heart failure based on ICD discharge codes with
positive predictive values of >90%; mortality
ascertained by linkage to social security master
beneficiary record database, which captures 95% of
deaths for older people
Sex, age, race, low income, extended care, Charlson score, cardiovascular
disease and drugs, lipid lowering drugs, and comorbidities
Hsiao 200918 Mean use of around 450 days
ascertainedwithprescriptionclaims
MI and heart failure ascertainment based on ICD codes
for inpatient claims
Data used in unadjusted form in meta-analysis
Juurlink 200919 Follow-up median of 292 days for
rosiglitazone and 294 days for
pioglitazone; ascertainment based
on computerised prescription
records
All cause mortality, MI, and heart failure obtained from
national ambulatory care reporting system database,
Canadian Institute for Health information discharge
database, and Ontario health insurance database
Age, sex, residence, socioeconomic status, year of entry, duration of
diabetes, acute MI, angina, congestive heart failure, coronary angiography,
CABG, PCI, Charlson index, history of renal disease, and previous drugs
(antihypertensives, aspirin, NSAIDs, nitroglycerin preparations, statins,
oral hypoglycaemics, digoxin)
Koro 200820 Follow-up mean of 2.1 years with
drug use window of 3 months,
inferred from prescription claims
Cases had ICD code for hospital admission for MI
occurring ≥3 months after diagnosis of diabetes;
controls were randomly selected from eligiblematched
patientswithin cohort who did not have ICD code forMI
Age; use of ACE inhibitors, β blockers, diuretic, or nitrate; hyperlipidaemia;
hypertension; and CAD
Lipscombe
200721
Unclear ascertainment; median
follow-up 3.8 years
MI, heart failure, and mortality data from registered
persons databases and hospital discharge summary
abstract database
Data used in unadjusted form in meta-analysis
Margolis 200822 Thiazolidinedione use on average
3.5 years; data based on
computerised prescription records
MI and coronary artery disease (MI, unstable angina,
cardiac death, coronary artery reperfusion procedure)
based on computerised read codes in general practice
database; approximately 3% lost to follow-up
Age; sex; BMI; HbA1C; smoking; chronic kidney disease; eGFR; mean
arterial blood pressure; and history of MI, unstable angina, or cardiac
procedure
Pantalone200923 Drug use at baseline based on
database information at single
healthcare centre
Heart failure and mortality data from ICD codes and
electronic health records database; small proportion of
mortality records from social security death index had
errors on cross checking and were corrected for
analysis
Age, sex, race, eGFR, albumin/urine creatinine ratio, HbA1C, BMI, systolic
blood pressure, diastolic blood pressure, HDL, LDL, triglycerides, smoking
status, cardiovascular drugs, new diabetes, and median household
income
Stockl 200924 Drug use based on prescription
claims from pharmacy database
MI cases based on ICD codes for hospital admission;
controls were matched on various parameters with
specific group constructed for analysis of rosiglitazone
v pioglitazone
Age, cardiovascular risk score, non-cardiovascular acute hospital
admission, COPD, and use of oestrogen therapy
Tzoulaki 200925 Drug use based on database
information; median follow-up
7.1 years
MI, heart failure, and mortality; unclear outcome
ascertainment
Age, sex, duration of diabetes, complications of diabetes, cardiovascular
and peripheral artery disease, co-prescribed drugs, BMI, cholesterol
concentration, systolic blood pressure, HbA1C, creatinine concentration,
albumin concentration, and smoking status
Walker 200826 Drug use from PharMetrics
database; mean on-treatment time
8 months and overall follow-up
ranged from 12 to 18 months
MIbasedonhospital dischargediagnosisand ICD code
as primary event
Propensity score used to adjust according to demographics, calendar time,
use of antidiabetic drugs, history of MI, coronary revascularisation, angina,
ACS, congestive heart failure, hyperlipidaemia, hypertension, obesity,
smoking, use of cardiovascular drugs
Wertz 201027 Drugs from pharmacy records;
unclear ascertainment; mean
duration of treatment 14.6 months
MI, heart failure, andmortality frommedical claims, ICD
codes, and national death index plus database; mean
follow-up 19.6 months
Propensity score used to adjust for age, sex, health plan, Deyo-Charlson
comorbidity index score, cardiovascular and peripheral vascular disease,
cardiovascular and antidiabetic drugs, obesity, smoking status, and
diabetic complications
Winkelmayer
200828
Drug use based on national drug
codes for prescription claims; mean
drug use around 215 days
Unclear how mortality was ascertained; MI and heart
failure data from Medicare claims
Cardiovascular disease, cerebrovascular disease, congestive heart failure,
previous insulin treatment, and nitrate use
Ziyadeh 200929 Use ascertained from pharmacy
claims database; mean follow-up
8.4 months with regimen stop as
censoring event
MI data from hospital discharge diagnosis and ICD
code as primary event; “sudden death” events
captured through ambulance codes for resuscitation/
intubation
Propensity score matching used with adjusted analysis for variety of
demographic and cardiovascular risk factors
ACS=acute coronary syndrome; BMI=body mass index; CABG=coronary artery bypass graft; CAD=coronary artery disease; COPD=chronic obstructive pulmonary disease; eGFR=estimated
glomerular filtration rate; HbA1c=glycated haemoglobin; HDL=high density lipoprotein cholesterol; ICD=international classification of diseases; LDL=low density lipoprotein cholesterol;
MI=myocardial infarction; NSAID=non-steroidal anti-inflammatory drug; PCI= percutaneous coronary intervention; TIA=transient ischaemic attack.
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As both drugs are known to cause heart failure, the
increasedriskofcongestiveheart failureassociatedwith
rosiglitazone comparedwithpioglitazone represents its
differentialcardiovasculartoxicity.Twointerpretations
for theirdifferential effectsonmyocardial infarctionare
possible.Onepossibility is that these findings represent
an ischaemic cardiovascular benefit with pioglitazone.
However, conclusive evidence on ischaemic cardio-
vascular benefit with pioglitazone is lacking; a meta-
analysis of trials yielded a relative risk of 0.81 (0.64 to
1.02) formyocardial infarction.Theotherpossibilityisa
greater ischaemic cardiovascular hazard with rosiglita-
zone, consistent with evidence from clinical trials.3 4
Possible biological mechanism
The precise biological mechanisms responsible for
these differences in cardiovascular risk and mortality
are uncertain. Significant differences have been found
between the thiazolidinediones in lipid metabolism;
rosiglitazone causes greater elevations of triglycerides
and low density lipoprotein cholesterol than does
pioglitazone.36 Pioglitazone had a significantly more
favourable effect on triglycerides, highdensity lipopro-
tein cholesterol, low density lipoprotein particle con-
centration, and low density lipoprotein particle size
than did rosiglitazone. Whereas pioglitazone has
shown some potential benefit in preventing progres-
sion of atherosclerosis,37 rosiglitazone failed to show
any significant effect in preventing atherosclerosis in
a recent study.38 Themore powerful renal PPARγ ago-
nistic effect of rosiglitazone, leading to more fluid
retention, may explain its greater risk of congestive
heart failure.39 40
Clinical and policy implications
Our findings have important implications. Rosiglita-
zone is still available on a restricted basis in the United
States and Canada.8 41 However, for patients who need
thiazolidinedione treatment, continueduse of rosiglita-
zonemay lead to excess heart attacks, heart failure, and
mortality, compared with pioglitazone. The size of the
effect on public health may be considerable, given the
data from June 2009 showing that about 3.8 million
prescriptions for rosiglitazone were dispensed
annually in the United States.42 However, other
adverse effects are associated with both the thiazolidi-
nediones, such as the doubling of risk of fracture in
women.7 Concerns also exist about a modest increase
in the risk of bladder cancer with pioglitazone after
long term use in an observational study and a higher
percentage of bladder cancers with pioglitazone rela-
tive to comparator arms in long term randomised con-
trolled trials.43 Further studies are needed to investigate
these other adverse events, as clinicians need to bal-
ance these risks and benefits against those of emerging
alternative agents such as incretinmimetics thatmayor
may not be safer than thiazolidinediones.
Limitations of study
Our analysis has some limitations, relating mainly to
the quality of the primary studies. Misclassification of
outcomes and drug usemay occur in observational stu-
dies that rely on healthcare databases and discharge
codes. However, any potential misclassification of
drug use and outcomes would affect both thiazolidine-
diones equally. Non-randomised data are susceptible
to selection bias and residual confounding. However,
investigators of the two largest cohort studies found
little difference in the baseline demographics and
cardiovascular risk of patients who used pioglitazone
and rosiglitazone.17 19 Both drugs are from the same
class and were licensed for similar indications. Until
May 2007, no reasons existed why any specific group
of patients would have been systematically channelled
towards one thiazolidinedione or the other. Our risk
estimates did not change despite exclusion of the two
Adjusted odds ratio
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studies that recruited after May 2007.17 19 Potential
exists for bias in selection of outcomes for analysis.
However, although selective reporting favouring sig-
nificant beneficial outcomes may occur, one cannot
assume that reporting bias is similarly focused on sig-
nificant findings of harm.The conversemayoccurwith
competing interests that emphasise interpretation and
reporting of safety in a manner that is favourable to
rosiglitazone.44 Finally, we had insufficient data to
assess effects on stroke or death from cardiac causes.
Conclusions
Our results show that among patients with type 2 dia-
betes, use of rosiglitazone is associated with a modest
but statistically significant increase in the odds of myo-
cardial infarction, congestive heart failure, and death
compared with patients receiving pioglitazone in real
world settings. Clinicians, patients, and regulatory
authorities should carefully consider these results in
the context of the available information on the thiazo-
lidinediones’ benefits on glycaemic control and harm
relating to different outcomes.
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